J Stroke Search

CLOSE


J Stroke > Volume 27(1); 2025 > Article
Li, Doheim, Qiu, Wang, Chen, Zi, Yang, Guan, Qiao, Liu, Hu, Liu, Huang, Han, Chen, Zhao, Sun, and Nogueira: Endovascular Treatment for Acute Posterior Circulation Tandem Lesions: Insights From the BASILAR and PERSIST Registries

Abstract

Background and Purpose

Limited evidence exists on the effectiveness of endovascular treatment (EVT) for acute posterior circulation tandem lesion (PCTL). This study aimed to explore the role of extracranial vertebral artery (VA) stenting in patients with PCTL stroke undergoing EVT.

Methods

Individual patient data were pooled from the BASILAR (EVT for Acute Basilar Artery Occlusion Study) and PERSIST (Posterior Circulation Ischemic Stroke) registries. Patients with PCTLs who underwent EVT were included in the present cohort and divided into the stenting and nonstenting groups based on the placement of extracranial VA stents. The primary efficacy outcome was the modified Rankin Scale (mRS) scores at 90 days and 1 year. Safety outcomes included 24-hour symptomatic intracranial hemorrhage (sICH) and all-cause mortality at 90 days and 1 year post-surgery.

Results

A combined dataset of 1,320 patients with posterior circulation artery occlusion, including 263 (19.9%) with tandem lesions, of whom 217 (median age, 65 years; 82.9% male) met the inclusion criteria for the analysis. The stenting group had 84 (38.7%) patients, while the non-stenting group had 133 (61.3%). After adjustment for the potential confounders, extracranial VA stenting was associated with favorable shifts in mRS scores at both 90 days (adjusted common odds ratio [OR], 2.30; 95% confidence interval [CI], 1.23-4.28; P<0.01) and 1 year (adjusted OR [aOR], 2.04; 95% CI [1.05-3.97]; P=0.04), along with lower rate of mortality at both 90 days (aOR, 0.45; 95% CI [0.21-0.93]; P=0.01) and 1 year (aOR, 0.36; 95% CI [0.16-0.79]; P=0.01), with no significant difference in sICH incidence (aOR, 0.35; 95% CI [0.06-1.98]; P=0.24).

Conclusion

Extracranial VA stenting during EVT may improve functional outcomes and reduce mortality in patients with PCTL strokes.

Introduction

Recent randomized clinical trials (ATTENTION [Endovascular Treatment for Acute Basilar-Artery Occlusion] and BAOCHE [Basilar Artery Occlusion Chinese Endovascular Trial]) in China have demonstrated the safety and efficacy of endovascular treatment (EVT) for patients with posterior circulation large vessel occlusion [1,2]. Posterior circulation tandem lesion (PCTL) is defined as a concomitant posterior circulation artery occlusion (PCAO) with severe stenosis (≥70%) or occlusion in the extracranial vertebral artery (VA), specifically in V1, V2, or proximal V3 segments [3]. PCTL occurs in 25%-29% of patients with acute posterior circulation stroke [4]. The treatment of tandem lesions represents a considerable challenge. There is little data on PCTLs, but in anterior circulation tandem lesions standard intravenous (IV) thrombolysis alone achieves recanalization in only 4% to 32% of cases, with good functional outcomes limited to only 17% of cases and with a death rate as high as 55% [5]. Patients with PCTL were excluded from most of the randomized controlled trials [1,2,6,7]. Therefore, despite the growing evidence supporting EVT for anterior circulation tandem occlusions, there is paucity of data regarding EVT in PCTL.
There are distinct anatomic considerations, including the dominance pattern of the VAs and the greater potential for collateral anastomosis, that preclude the extrapolation of EVT data from anterior to posterior circulation tandem occlusions [8]. While some recent studies have shown that EVT for PCTL is both safe and feasible [9-14], there is currently no consensus about the ideal technical strategies for tandem lesions, with uncertainties surrounding which of the two VAs to approach (e.g., the “clean- vs. dirty-road” approaches) as well as which recanalization strategy to use for the extracranial steno-occlusive lesion. The treatment for extracranial VA varies from no intervention to acute angioplasty with or without stenting. Given these challenges, this study aims to compare strategies for extracranial VA lesions in patients undergoing EVT for acute ischemic stroke (AIS) due to PCTL, using data from two large multicenter prospective registries.

Methods

Patients and study design

This post hoc analysis pooled data from two observational studies: the BASILAR (EVT for Acute Basilar Artery Occlusion Study; http://www.chictr.org.cn; ChiCTR1800014759) and PERSIST (Posterior Circulation Ischemic Stroke; http://www.chictr.org.cn; ChiCTR2000033211) registries, previously described in detail. Briefly, BASILAR prospectively recruited patients treated with EVT at 47 comprehensive stroke centers across 15 provinces in China from January 2014 to May 2019 [15]. PERSIST, a retrospective multicenter registry, included patients treated with EVT at 21 stroke centers in China from December 2015 to December 2018 [16]. The inclusion criteria for the current analysis were: (1) age ≥18 years, (2) presentation within 24 hours of PCTL onset, (3) presence of PCTL confirmed by computed tomography angiography, magnetic resonance angiography, or digital subtraction angiography; (4) use of EVT with contemporary technology including stent retriever and/or contact aspiration catheters.
PCTL was defined as an intracranial occlusion involving the intracranial VA, the proximal (from the vertebrobasilar junction to the origin of the anterior inferior cerebellar artery), middle (from the origin of the anterior inferior cerebellar artery to the origin of the superior cerebellar artery), or distal (distal to the origin of the superior cerebellar artery) basilar artery, or the posterior cerebral artery, and an extracranial VA steno-occlusive lesion (stenosis ≥70% or complete occlusion, as defined by North American Symptomatic Carotid Endarterectomy [NASCET] Trial) [17]. The neurointerventional approach of extracranial VA was based on the operator’s preference and included extracranial VA stenting with/without angioplasty (stenting group) or EVT without extracranial VA stenting (non-stenting group). The non-stenting group included patients who did not undergo EVT for extracranial VA lesions or who were treated with angioplasty alone. Given the retrospective study design and use of de-identified data, this study was approved under a waiver of informed consent by the local institutional review boards at each participating center (BASILAR 2013-087-01; PERSIST 2020 KY-40) and was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Outcome measures

The primary efficacy outcome was the modified Rankin Scale (mRS) score at 90 days and 1 year, ranging from 0 (no residual symptoms) to 6 (death), with 3 indicating moderate disability but independent walking, assessed by blinded local neurologists. The secondary clinical efficacy outcome was the rate of favorable functional outcomes (mRS scores of 0-3) at 90 days and 1 year. Technical efficacy was measured by the rate of successful revascularization, defined as a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b or 3, indicating reperfusion of ≥50% of the affected vascular territory. Safety outcomes included symptomatic intracranial hemorrhage (sICH) within 24 hours and all-cause mortality at 90 days and 1 year, with intracranial hemorrhage classified according to the Heidelberg Bleeding Classification [18]. Procedural complications included vessel perforation, arterial dissection, distal embolization, and vasospasm.

Antiplatelet management

To prevent thrombosis after stent implantation and reocclusion of residual stenosis, IV tirofiban (a glycoprotein IIb/IIIa inhibitor) was administered. If stent implantation during the operation was necessary, tirofiban was administered 5 minutes before stent deployment. Continuous tirofiban infusion at 2/3 of the recommended cardiac dose was started after excluding any significant hemorrhagic complications, with a post-procedure head computed tomography (CT) performed immediately after the procedure and continued for 24 hours. The patients were subsequently administered clopidogrel and aspirin after excluding any significant intracranial hemorrhage (ICH) on repeat head CT at 24 hours. Tirofiban infusion was stopped 6 hours after aspirin and clopidogrel loading, and regular doses of aspirin (100 mg) and clopidogrel (75 mg) were administered starting the following day.

Statistical analysis

Data are presented as medians (interquartile range [IQR]) or frequencies with percentages unless otherwise indicated. Univariate analysis was performed using the Mann-Whitney U test, χ2 test, or Fisher exact test, as appropriate. The effect size of the primary outcome was adjusted for the common odds ratio (cOR) and estimated using multivariable ordinal logistic regression. The effect size of other outcomes was adjusted for odds ratios (ORs) and calculated using multivariable binary logistic regression. Unadjusted and adjusted effect sizes are reported with 95% confidence intervals (CI) to indicate statistical precision. Age, diabetes mellitus, hyperglycemia, current smoking status, presence of atrial fibrillation, baseline National Institutes of Health Stroke Scale (NIHSS) score, baseline posterior circulation Acute Stroke Prognosis Early CT Score (pc-ASPECTS), first-line treatment, and postoperative IV tirofiban use were included in the multivariable regression models. Statistical testing was done at the 2-tailed α-level of 0.05. Data were analyzed using R version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria).

Results

Baseline and procedural characteristics

The combined dataset yielded 1,320 patients with PCAO treated with EVT across the two registries (BASILAR, n=647; PERSIST, n=673), including 263 (19.9%) patients presenting with tandem lesions (110 from BASILAR and 153 from PERSIST). Among the 263 tandem patients, 217 (median [IQR] age, 65 [56-73] years; baseline NIHSS score, 23 [13-30]; baseline pc-ASPECTS, 9 [7-10]; 180 men [82.9%]) met the study criteria and were included in the final analysis (Figure 1). A total of 84 (38.7%) and 133 (61.3%) patients were included in the stenting and non-stenting groups, respectively. Overall, 52 (24.0%) patients received intravenous thrombolysis (IVT) before the endovascular procedure, and 133/216 (61.6%) were treated under general anesthesia. The first-line mechanical thrombectomy technique was the stent retriever alone in 73.3% (159/217), combined stent retriever and contact aspiration in 21.2% (46/217), and contact aspiration alone in 5.5% (12/217) of the cases (Table 1).
Compared with the non-stenting patients, stenting patients were younger (63 [53.5-68] vs. 66 [57-75] years, P=0.04), had a lower rate of atrial fibrillation (3.6% vs. 15.8%, P=0.02), and had a higher proportion of IV tirofiban use (55/77 [71.4%] vs. 58/104 [55.8%], P=0.03). The median NIHSS scores at baseline (24.5 [15-30.5] vs. 23 [12-30], P=0.49) and IVT rates (16 [19.1%] vs. 36 [27.1%], P=0.19) were similar between the two groups. In the stenting group, intracranial occlusion was more often treated with a stent retriever alone as the first-line treatment (81.0% vs. 68.4%, P=0.02), whereas the combined technique was more often used in the non-stenting group (11.9% vs. 27.1%, P=0.02). The time from puncture to recanalization was 25 minutes longer in the stenting group than in the non-stenting group (140 [105-176] vs. 115 [80-175] minutes, P=0.03). Other baseline and procedural characteristics were not significantly different between the two groups (Table 1).

Primary efficacy outcome

After adjusting for age, diabetes mellitus, hyperglycemia, current smoking, presence of atrial fibrillation, baseline NIHSS score, baseline pc-ASPECTS, first-line treatment, and postoperative IV tirofiban use, there was a significant improvement in the distribution of the mRS score at both 90-days (adjusted cOR, 2.30; 95% CI, 1.23-4.28; P<0.01) and 1 year (adjusted OR [aOR], 2.04; 95% CI, 1.05-3.97; P=0.04) favoring the stenting group (Table 2 and Figure 2).

Secondary efficacy outcomes

The secondary clinical and technical efficacy outcomes of recanalization are shown in Table 2 and Figures 2 and 3. The rate of favorable outcomes (mRS score ≤3) at 90 days and 1 year was 39.5% (85/215) and 41.2% (86/209) for all patients with PCTL, respectively. The proportion of favorable outcomes (mRS score ≤3) at 90 days (37/84 [44.1%] vs. 48/131 [36.6%]; aOR: 2.47 [95% CI, 1.04-5.89]; P=0.04) was significantly higher in the stenting than in the non-stenting group. However, no statistically significant differences were observed at 1 year (35/81 [43.2%] vs. 51/128 [39.8%]; aOR: 1.50 [95% CI, 0.64-3.52]; P=0.35). Although not statistically significant, there was a trend toward a higher rate of successful recanalization in the stenting group compared with the non-stenting group (78/84 [92.9%] vs. 112/133 [84.2%]; aOR: 2.53 [95% CI, 0.88-7.31]; P=0.09).

Safety outcomes

The rate of mortality was significantly lower in the stenting as compared to the non-stenting patients at both 90 days (29/84 [34.5%] vs. 57/131 [43.5%]; aOR: 0.45 [95% CI, 0.21-0.93]; P=0.01) and 1 year (32/81 [39.5%] vs. 67/128 [52.3%]; aOR: 0.36 [95% CI, 0.16-0.79]; P=0.01). The rate of sICH was 3.6% (3/84) in the stenting and 9.2% (12/131) in the non-stenting (aOR: 0.35 [95% CI, 0.06-1.98]; P=0.24) group (Table 2). Device-associated or procedural complications were observed in 31 patients (14.3%), with no significant differences in the rates of arterial perforation, dissection, distal embolization, vasospasm, or vascular rupture between the two groups. The rates of other serious adverse events during the 90-day follow-up period were similar between the two treatment groups (Table 1).

Discussion

To the best of our knowledge, the current analysis represents the largest study of consecutive patients who underwent EVT for acute symptomatic PCTL. The primary findings of our study are as follows: First, tandem lesions are relatively common in the posterior circulation, representing approximately one-fifth of all acute PCAO; Second, given the overall comparable baseline characteristics and outcomes to what has been reported in the recent randomized controlled trials (RCTs) of non-tandem PCAO, patients with AIS and confirmed acute symptomatic PCTL appear to benefit with respect to functional recovery when EVT is administered within 24 hours of estimated occlusion time; Third, compared with no extracranial VA stenting, treatment with acute extracranial VA stenting seems to be associated with better functional outcomes and lower mortality rate at 90 days without increasing the risk of sICH.
In the present study, PCTLs accounted for 19.9% of all posterior circulation large vessel occlusions, which is consistent with the available literature on posterior circulation tandem occlusions (approximately 25%-29%) [3,11,12,19,20] and comparable to what is observed in the anterior circulation (17%-32%) [21-23]. PCTLs frequently lead to severe strokes, yet they remain a poorly understood subtype of acute posterior circulation strokes [24]. Currently, literature on the outcomes of EVT for PCTL patients is limited, predominantly from single-center studies. The reported mortality rates ranged from 20% to 42.9%, with only 28.6% to 53.3% of patients achieving functional independence (mRS 0-2) [9-12,25-27]. Notably, the rate of favorable outcomes (90-day mRS 0-3) in our PCTL population (39.5%) was comparable to that observed in the BEST (Endovascular Interventions Versus Standard Medical Treatment), BASICS (Basilar Artery International Cooperation Study), ATTENTION, and BAOCHE RCTs of non-tandem PCAOs (42%, 44.2%, 46%, and 46%, respectively). Similarly, the rate of successful recanalization (mTICI 2b-3) in our PCTL cohort (87.6%) aligned with the rates reported in non-tandem PCAO RCTs (71%, 72%, 93%, and 88%). Furthermore, the rates of sICH (7.0% vs. 8%, 4.5%, 5%, and 9%) and 90-day mortality (40.0% vs. 33%, 38.3%, 37%, and 31%) were also consistent with data from non-tandem PCAOs trials [1,2,6,7]. These findings suggest that EVT for acute PCTL may be beneficial with an acceptable safety profile.
Our findings are also consistent with several previously published studies of anterior circulation tandem occlusions that reported clinical outcomes favoring acute stenting in tandem lesions [28-31]. Patients in the stenting group were significantly younger and had a lower rate of atrial fibrillation than those in the non-stenting group. These factors may have influenced the neurointerventionist’s decision to opt for stenting [32]. Both the modified first-pass effect (mTICI 2b-3; 29.8% vs. 24.8%) and recanalization rate (mTICI 2b-3; 92.9% vs. 82.2%) were numerically higher with stenting than non-stenting but these difference were not statistically significant. The puncture-to-recanalization time was longer (25 minutes) in the stenting group. Nonetheless, we observed a statistically significant shift in the distribution of mRS scores and 90-day favorable outcomes, favoring better outcomes in the stent placement group after adjusting for these confounders.
Regarding safety, one of the most concerning complications associated with stent use is the risk of hemorrhagic transformation. This risk arises from abrupt hemodynamic changes in the presence of significant ischemic injury and the early requirement for post-stroke antiplatelet agents, particularly in patients who receive IVT before the intervention. In our study, there was no evidence of heterogeneity according to thrombolysis treatment, although a higher proportion of patients in the stenting group received postoperative IV tirofiban. Importantly, the rate of sICH did not differ significantly between the two groups in adjusted analysis and was lower than rates reported in trials involving anterior circulation tandem occlusions (approximately 10% to 20%) [33-35]. These findings align with non-tandem PCAO trials, indicating a lower risk of hemorrhagic transformation in posterior circulation strokes compared to anterior circulation strokes [36-40]. This difference may be attributed to greater tolerance to ischemic injury, likely due to smaller infarct volumes, the predominance of white matter structures, and the presence of robust collateral pathways, particularly in the brainstem [41,42].
A previous study showed short-term reocclusion of the basilar artery after successful mechanical thrombectomy in 2 of the 6 patients who had been treated via the contralateral route without angioplasty or stent of the tandem VA lesion [3]. Kawano et al. [43] suggested that poorly organized thrombi in the ostial VA and the loss of downstream flow resistance following sudden mechanical recanalization of the basilar artery may be significant factors contributing to recurrent large vessel embolic occlusion.
The main advantages of extracranial VA stenting are most likely related to the augmentation of perfusion with a widely patent VA [44]. Moreover, it may decrease the risk of recurrent strokes from unstable atherosclerotic plaque embolization, subsequently decreasing the risk of early neurological deterioration and mortality. In our study, we found a significantly lower rate of early neurological deterioration and mortality at 90 days in the stenting group than in the non-stenting group. Furthermore, the cumulative 1-year mortality rate was significantly lower in the stenting group than in the non-stenting group (39.5% vs. 52.3%; P=0.01, with an aOR of 0.36, 95% CI, 0.16-0.79). The beneficial impact of acute stenting on mortality, sustained for at least 1 year, and further highlight the importance of stents in patients with acute PCTL. However, this statement cannot be verified because the BASILAR and PERSIST registries do not require followup for post-procedural VA patency verification. Additionally, the use of dual antiplatelet therapy in the post-stenting group may have played a role in secondary stroke prevention and reduction of recurrent events [45].
Our study had several significant limitations. First, there is an inherent potential for selection bias owing to its retrospective design and the absence of a control group comprising medical patients. The decision regarding the treatment of extracranial VA stenosis was left to the discretion of the operator, and the antiplatelet regimen was not standardized. Second, angiographic CT (ACT) is an effective method for assessing pre-stenting intracerebral hemorrhage. The BASILAR and PERSIST studies were initiated in China in 2024 and 2015, respectively, during which some stroke centers had access to ACT, while others did not. If a suspicious intracerebral hemorrhage was identified through ACT, these factors may have influenced the proceduralist’s decision to proceed with the stenting. Third, the status of the contralateral VA may affect the decision to proceed with stenting during the procedure and should be considered in this analysis; however, we were unable to conduct this analysis owing to the unavailability of the contralateral VA status in some cases. Fourth, long-term follow-up imaging data regarding VA patency were not available. Patency rates of the stents following the procedures were assessed in only 21 patients; among them, two experienced restenosis, and two had reocclusion. Finally, this study exclusively enrolled Han Chinese patients who exhibit a high prevalence of extracranial large-artery atherosclerosis; thus, our findings may not be generalizable to Western populations.

Conclusions

This observational registry-based study provides evidence supporting the safety and efficacy of EVT in patients with PCTL-induced AIS caused by PCTL treated within 24 hours of the estimated occlusion time. Our data also suggest that acute extracranial VA stenting during mechanical thrombectomy may enhance functional outcomes and reduce mortality rates in patients with PCTL. Similar to anterior circulation tandem occlusions [46], RCTs investigating optimal endovascular management in PCTL are warranted.

Notes

Funding statement
This project was supported by the Hainan Provincial Natural Science Foundation of China (Grant No. 823RC586) and the Research Funds of the Center for Leading Medicine and Advanced Technologies of IHM (Grant No. 2023IHM01050).
Conflicts of interest
RGN reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron, and stock options for advisory roles with astrocytes, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular Inc., Vesalio, Viz-AI, RapidPulse, and Perfuze. RGN is one of the Principal Investigators of the “Endovascular Therapy for Low NIHSS Ischemic Strokes (ENDOLOW)” trial. The funding for this project was provided by Cerenovus. RGN is the Principal Investigator of the “Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe (DUSK)” trial. Funding for this project was provided by Stryker Neurovascular Co.. RGN is an investor in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, Tulavi Therapeutics, Vastrax, Piraeus Medical, Brain- 4Care, Quantanosis AI, and Viseon. The remaining authors have no financial conflicts of interest.
Author contribution
Conceptualization: RGN, ZZ, XL. Study design: WL, MFD, TW, ZC. Methodology: MFD, ZQ, HG, HQ, WL. Data collection: ZQ, WS, WZ, QY, JH, ZH, ZC. Statistical analysis: MFD, ZQ. Writing—original draft: WL, ZQ. Writing—review & editing: RGN, ZZ, WH. Funding acquisition: WL, ZZ. Approval of final manuscript: all authors.

Acknowledgments

We are grateful for the dedication of all co-investigators of BASILAR and PERSIST to the study.

Figure 1.
Flowchart of patient selection. EVT, endovascular treatment; BASILAR, EVT for Acute Basilar Artery Occlusion Study; PERSIST, Posterior Circulation Ischemic Stroke; MT, mechanical thrombectomy; IA, intra-arterial.
jos-2024-03055f1.jpg
Figure 2.
Distribution of modified Rankin Scale (mRS) score at 90 days between the stenting and non-stenting groups (mRS ordinal shift: adjusted common odds ratio 2.08, 95% confidence interval [1.09-3.95], P=0.03).
jos-2024-03055f2.jpg
Figure 3.
Distribution of modified Rankin Scale (mRS) score at 1 year between the stenting and non-stenting groups (mRS ordinal shift: adjusted common odds ratio 1.81, 95% confidence interval [0.95-3.46], P=0.07).
jos-2024-03055f3.jpg
Table 1.
Baseline characteristics according to the use of extracranial vertebral artery stent in the overall cohort
Characteristic Total (n=217) Stenting (n=84) Non-stenting (n=133) P
Demographics characteristics
 Age (yr) 65 (56-73) 63 (53.5-68) 66 (57-75) 0.04
 Male sex 180 (82.9) 73 (86.9) 107 (80.5) 0.22
Medical history
 Hypertension 147 (67.7) 59 (70.2) 88 (66.2) 0.53
 Diabetes mellitus 53 (24.4) 22 (26.2) 31 (23.3) 0.63
 Hyperglycemia 68 (31.3) 29 (34.5) 39 (29.3) 0.42
 Atrial fibrillation 34 (15.7) 9 (10.7) 25 (18.8) 0.11
 Coronary artery disease 19 (8.8) 4 (4.8) 15 (11.3) 0.09
 Current smoking 68/216 (31.5) 28 (33.3) 40/132 (30.3) 0.64
 History of stroke 32 (14.8) 15 (17.9) 17 (12.8) 0.30
 History of TIA 15 (6.9) 3 (3.6) 12 (9.0) 0.12
Clinical examination
 Baseline SBP (mm Hg) 150 (132-173.5) 151 (131-178) 150 (135-168) 0.99
 Baseline DBP (mm Hg) 83 (76-97) 83 (76-100) 83 (75-96) 0.63
 Serum glucose (mmol/L) 7.3 (6.1-9.4) 7.3 (6.2-8.9) 7.5 (6.1-9.7) 0.50
 Baseline NIHSS 23 (13-30) 24.5 (15-30.5) 23 (12-30) 0.49
 Baseline Glasgow 8 (6-12) 8 (6-12) 7 (5-12) 0.54
Etiology of extracranial VA lesion 0.02
 Large-artery atherosclerosis 163 (75.1) 67 (79.8) 96 (72.2)
 Cardioembolism 24 (11.1) 3 (3.6) 21 (15.8)
 Others or unknown 30 (13.8) 14 (16.7) 16 (12.0)
Imaging characteristics
 Baseline pc-ASPECTS 9 (7-10) 8 (7-10) 9 (7-10) 0.24
 ASITN/SIR grade (2-4) 62 (28.7) 27 (32.5) 35 (26.3) 0.33
 Basilar-artery occlusion site 0.97
  Vertebral artery V4 52 (24.0) 21 (25.0) 31 (23.3)
  Proximal basilar artery 47 (21.7) 17 (20.3) 30 (22.6)
  Middle basilar artery 50 (23.0) 21 (25.0) 29 (21.8)
  Distal basilar artery 62 (28.6) 23 (27.4) 39 (29.3)
  Posterior cerebral artery 6 (2.7) 2 (2.4) 4 (3.0)
 Tandem VA occlusion site 0.30
  Vertebral artery V1 164 (75.6) 67 (79.8) 97 (72.9)
  Vertebral artery V2 18 (8.3) 4 (4.8) 14 (10.5)
  Vertebral artery V3 35 (16.1) 13 (15.5) 22 (16.5)
EVT characteristics
 Intravenous thrombolysis 52 (24.0) 16 (19.1) 36 (27.1) 0.19
 Adjuvant treatment (IA tirofiban) 59 (27.2) 29 (34.5) 30 (22.6) 0.05
 Postoperative Medication (IV tirofiban) 113/181 (62.4) 55/77 (71.4) 58/104 (55.8) 0.03
 General anesthesia 133/216 (61.6) 54/83 (65.1) 79 (59.4) 0.41
 First-line strategy 0.02
  Stent retriever 159 (73.3) 68 (81.0) 91 (68.4)
  ADAPT 12 (5.5) 6 (7.1) 6 (4.5)
  Stent retriever+ADAPT 46 (21.2) 10 (11.9) 36 (27.1)
 Number of passes 1 (1-2) 1 (1-2) 2 (1-2) 0.09
Workflow measures
 Last known well to puncture time (min) 317.5 (226.5-491) 339 (225-525) 309 (228-450) 0.57
 Time from puncture to recanalization (min) 130 (90-176) 140 (105-176) 115 (80-175) 0.03
 Last known well to recanalization time (min) 448 (342-628) 469 (344.5-681.5) 440 (340-600) 0.33
Procedure-related complication
 Arterial perforation 1 (0.5) 1 (1.2) 0 0.20
 Dissection 9 (4.2) 3 (3.6) 6 (4.5) 0.74
 Distal embolization 7 (3.2) 2 (2.4) 5 (3.8) 0.58
 Vasospasm 3 (1.4) 0 3 (2.3) 0.17
 Vascular rupture 11 (5.1) 4 (4.8) 7 (5.3) 0.87
Other serious adverse events
 Pulmonary infection 142 (65.4) 56 (66.7) 86 (64.7) 0.76
 Respiratory failure 86 (39.6) 35 (41.7) 51 (38.4) 0.63
 Circulatory failure 35 (16.1) 10 (11.9) 25 (18.8) 0.18
 Ulcer 25 (11.5) 9 (10.7) 16 (12.0) 0.77
 Venous thrombosis 5 (2.3) 3 (3.6) 2 (1.5) 0.32
Values are presented as median (interquartile range) or n (%).
TIA, transient ischemia attack; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institutes of Health Stroke Scale; VA, vertebral artery; pc-ASPECTS, posterior circulation Acute Stroke Prognosis Early CT Score; ASITN/SIR, American Society of Interventional and Therapeutic Neuroradiology/Society of Interventional Radiology System; EVT, endovascular treatment; ADAPT, a direct aspiration first pass technique; IA, intra-arterial; IV, intravenous.
Table 2.
Comparisons in clinical and procedural outcomes according to the use of extracranial vertebral artery stent in the overall study sample (main analysis)
Outcomes Stenting (n=84) Non-stenting (n=133) Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Primary efficacy outcome
 mRS score at 90 days 4 (1-6) 5 (2-6) 0.72 (0.44-1.18)* 0.20 2.30 (1.23-4.28)* <0.01
Secondary efficacy outcomes
 90-day mRS (0-3) 37 (44.1) 48/131 (36.6) 1.36 (0.78-2.38) 0.28 2.47 (1.04-5.89) 0.04
 90-day mRS (0-2) 27 (32.1) 37/131 (28.2) 1.20 (0.66-2.18) 0.54 1.90 (0.80-4.53) 0.15
 90-day mRS (0-1) 21 (25.0) 20/131 (15.5) 1.85 (0.93-3.67) 0.08 3.48 (1.26-9.61) 0.02
 mRS score at 1 year 4 (1-6) 6 (1-6) 0.71 (0.43-1.19) 0.19 2.04 (1.05-3.97) 0.04
 1-year mRS (0-3) 35/81 (43.2) 51/128 (39.8) 1.16 (0.66-2.05) 0.60 1.50 (0.64-3.52) 0.35
 1-year mRS (0-2) 34/81 (42.0) 42/128 (32.8) 1.50 (0.84-2.66) 0.17 2.41 (0.98-5.96) 0.06
 1-year mRS (0-1) 26/81 (32.1) 35/128 (27.3) 1.27 (0.69-2.33) 0.44 1.74 (0.72-4.24) 0.22
Safety outcomes
 90-day mortality 29 (34.5) 57/131 (43.5) 0.69 (0.39-1.21) 0.19 0.45 (0.21-0.93) 0.01
 1-year mortality 32/81 (39.5) 67/128 (52.3) 0.59 (0.33-1.03) 0.06 0.36 (0.16-0.79) 0.01
 Symptomatic ICH 3 (3.6) 12/131 (9.2) 0.37 (0.10-1.34) 0.13 0.35 (0.06-1.98) 0.24
 END 13 (15.5) 34 (25.6) 0.53 (0.26-1.08) 0.08 0.38 (0.16-0.89) 0.03
Procedural outcomes
 mFPE (mTICI 2b-3) 25 (29.8) 33 (24.8) 1.28 (0.70-2.37) 0.42 2.15 (0.95-4.88) 0.07
 Successful reperfusion 78 (92.9) 112 (84.2) 2.44 (0.94-6.32) 0.07 2.53 (0.88-7.31) 0.09
Values are presented as median (interquartile range) or n (%) unless otherwise noticed. The following variables were adjusted for in the analysis: age, diabetes mellitus, hyperglycemia, current smoking, presence of atrial fibrillation, baseline NIHSS score, baseline pc-ASPECTS, first-line treatment, and postoperative IV tirofiban use.
OR, odds ratio; CI, confidence interval; mRS, modified Rankin Scale; ICH, intracranial hemorrhage; END, early neurological deterioration; mFPE, modified firstpass effect; mTICI, modified Thrombolysis in Cerebral Infarction; NIHSS, National Institutes of Health Stroke Scale; pc-ASPECTS, posterior circulation Acute Stroke Prognosis Early CT Score; IV, intravenous.
* Common odds ratio (95% CI).

References

1. Tao C, Nogueira RG, Zhu Y, Sun J, Han H, Yuan G, et al. Trial of endovascular treatment of acute basilar-artery occlusion. N Engl J Med 2022;387:1361-1372.
pmid
2. Jovin TG, Li C, Wu L, Wu C, Chen J, Jiang C, et al. Trial of thrombectomy 6 to 24 hours after stroke due to basilar-artery occlusion. N Engl J Med 2022;387:1373-1384.
pmid
3. Baik SH, Jung C, Kim BM, Kim DJ. Mechanical thrombectomy for tandem vertebrobasilar stroke: characteristics and treatment outcome. Stroke 2020;51:1883-1885.
crossref pmid
4. Weinberg JH, Sweid A, Sajja K, Abbas R, Asada A, Kozak O, et al. Posterior circulation tandem occlusions: classification and techniques. Clin Neurol Neurosurg 2020;198:106154.
crossref pmid
5. Papanagiotou P, Haussen DC, Turjman F, Labreuche J, Piotin M, Kastrup A, et al. Carotid stenting with antithrombotic agents and intracranial thrombectomy leads to the highest recanalization rate in patients with acute stroke with tandem lesions. JACC Cardiovasc Interv 2018;11:1290-1299.
crossref pmid
6. Liu X, Dai Q, Ye R, Zi W, Liu Y, Wang H, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion (BEST): an open-label, randomised controlled trial. Lancet Neurol 2020;19:115-122.
pmid
7. Langezaal LCM, van der Hoeven EJRJ, Mont’Alverne FJA, de Carvalho JJF, Lima FO, Dippel DWJ, et al. Endovascular therapy for stroke due to basilar-artery occlusion. N Engl J Med 2021;384:1910-1920.
crossref pmid
8. Cohen JE, Leker RR, Gomori JM, Eichel R, Rajz G, Moscovici S, et al. Emergent revascularization of acute tandem vertebrobasilar occlusions: endovascular approaches and technical considerations-confirming the role of vertebral artery ostium stenosis as a cause of vertebrobasilar stroke. J Clin Neurosci 2016;34:70-76.
crossref pmid
9. Ecker RD, Tsujiura CA, Baker CB, Cushing D. Endovascular reconstruction of vertebral artery occlusion prior to basilar thrombectomy in a series of six patients presenting with acute symptomatic basilar thrombosis. J Neurointerv Surg 2014;6:379-383.
crossref pmid
10. Yang H, Ma N, Zhang S, Huo X, Gao F, Sun X, et al. Endovascular revascularisation of acute tandem vertebrobasilar artery occlusion: seven case series with literature reviews. Stroke Vasc Neurol 2018;3:17-21.
crossref pmid pmc
11. Piechowiak EI, Kaesmacher J, Zibold F, Dobrocky T, Mosimann PJ, Jung S, et al. Endovascular treatment of tandem occlusions in vertebrobasilar stroke: technical aspects and outcome compared with isolated basilar artery occlusion. J Neurointerv Surg 2020;12:25-29.
crossref pmid
12. Liang K, Wang B, Zhao L, Cao Y, Jiang L, Liu Q, et al. Management of posterior circulation tandem occlusions in acute ischemic stroke: recanalize the dominant vertebral artery with priority. Interv Neuroradiol 2023;29:570-576.
crossref pmid pmc pdf
13. Baik SH, Park HJ, Kim JH, Jang CK, Kim BM, Kim DJ. Mechanical thrombectomy in subtypes of basilar artery occlusion: relationship to recanalization rate and clinical outcome. Radiology 2019;291:730-737.
crossref pmid
14. Mahmoud MN, Zaitoun MMA, Abdalla MA. Revascularization of vertebrobasilar tandem occlusions: a meta-analysis. Neuroradiology 2022;64:637-645.
crossref pmid pdf
15. Zi W, Qiu Z, Wu D, Li F, Liu H, Liu W, et al. Assessment of endovascular treatment for acute basilar artery occlusion via a nationwide prospective registry. JAMA Neurol 2020;77:561-573.

16. Lu Y, Wu Z, Wang Z, Zhang P, Zhang F, Hu M, et al. Rescue stenting after failure of endovascular thrombectomy for acute vertebrobasilar artery occlusion: data from the PERSIST registry. J Neurointerv Surg 2024;16:347-351.
crossref pmid
17. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med 1998;339:1415-1425.
crossref pmid
18. von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, et al. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015;46:2981-2986.
crossref pmid
19. Siebert E, Bohner G, Zweynert S, Maus V, Mpotsaris A, Liebig T, et al. Revascularization techniques for acute basilar artery occlusion: technical considerations and outcome in the setting of severe posterior circulation steno-occlusive disease. Clin Neuroradiol 2019;29:435-443.
crossref pmid pdf
20. Baik SH, Kim JY, Jung C. A review of endovascular treatment for posterior circulation strokes. Neurointervention 2023;18:90-106.
crossref pmid pmc pdf
21. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.
pmid
22. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-2306.
crossref pmid
23. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. N Engl J Med 2015;372:1019-1030.
pmid
24. Puri AS, Kühn AL, Kwon HJ, Khan M, Hou SY, Lin E, et al. Endovascular treatment of tandem vascular occlusions in acute ischemic stroke. J Neurointerv Surg 2015;7:158-163.
crossref pmid
25. Jiang L, Yang JH, Ruan J, Xia WQ, Huang H, Zhang H, et al. A single-center experience of endovascular treatment in subtypes of basilar artery occlusion: embolization caused by tandem vertebral artery stenosis may be associated with better outcomes. World Neurosurg 2021;151:e918-e926.
crossref pmid
26. Xing PF, Zhang YW, Li ZF, Zhang L, Shen HJ, Zhang YX, et al. The “distal-to-proximal” strategy for the treatment of posterior circulation tandem occlusions: a single-centre experience. Neuroradiology 2020;62:867-876.
crossref pmid pdf
27. Elhorany M, Boulouis G, Hassen WB, Crozier S, Shotar E, Sourour NA, et al. Outcome and recanalization rate of tandem basilar artery occlusion treated by mechanical thrombectomy. J Neuroradiol 2020;47:404-409.
crossref pmid
28. Anadani M, Marnat G, Consoli A, Papanagiotou P, Nogueira RG, Siddiqui A, et al. Endovascular therapy of anterior circulation tandem occlusions: pooled analysis from the TITAN and ETIS registries. Stroke 2021;52:3097-3105.
pmid
29. Anadani M, Spiotta AM, Alawieh A, Turjman F, Piotin M, Haussen DC, et al. Emergent carotid stenting plus thrombectomy after thrombolysis in tandem strokes: analysis of the TITAN registry. Stroke 2019;50:2250-2252.
crossref pmid
30. Li W, Chen Z, Dai Z, Liu R, Yin Q, Wang H, et al. Management of acute tandem occlusions: stent-retriever thrombectomy with emergency stenting or angioplasty. J Int Med Res 2018;46:2578-2586.
crossref pmid pmc pdf
31. Farooqui M, Zaidat OO, Hassan AE, Quispe-Orozco D, Petersen N, Divani AA, et al. Functional and safety outcomes of carotid artery stenting and mechanical thrombectomy for large vessel occlusion ischemic stroke with tandem lesions. JAMA Netw Open 2023;6:e230736.
crossref pmid pmc
32. Zevallos CB, Farooqui M, Quispe-Orozco D, Mendez-Ruiz A, Patterson M, Below K, et al. Proximal internal carotid artery acute stroke secondary to tandem occlusions (PICASSO) international survey. J Neurointerv Surg 2021;13:1106-1110.
crossref pmid
33. Feil K, Herzberg M, Dorn F, Tiedt S, Küpper C, Thunstedt DC, et al. Tandem lesions in anterior circulation stroke: analysis of the German stroke registry-endovascular treatment. Stroke 2021;52:1265-1275.
crossref pmid
34. Li W, Zhao C, Zhang M, Yang S, Zhao Z, Wang T, et al. Angioplasty alone versus acute stenting for acute tandem occlusions due to internal carotid artery atherosclerotic. Clin Neurol Neurosurg 2021;208:106818.
crossref pmid
35. Heck DV, Brown MD. Carotid stenting and intracranial thrombectomy for treatment of acute stroke due to tandem occlusions with aggressive antiplatelet therapy may be associated with a high incidence of intracranial hemorrhage. J Neurointerv Surg 2015;7:170-175.
crossref pmid
36. Sarikaya H, Arnold M, Engelter ST, Lyrer PA, Mattle HP, Georgiadis D, et al. Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke. Stroke 2011;42:2498-2502.
crossref pmid
37. Keselman B, Gdovinová Z, Jatuzis D, Melo TPE, Vilionskis A, Cavallo R, et al. Safety and outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke: results from the safe implementation of treatments in stroke registry and meta-analysis. Stroke 2020;51:876-882.
crossref pmid
38. Puetz V, Lutsep HL, Nguyen TN. Endovascular therapy for basilar artery occlusion: among the first to conceptualize, last to prove. Stroke 2023;54:905-908.
crossref pmid
39. Alemseged F, Nguyen TN, Coutts SB, Cordonnier C, Schonewille WJ, Campbell BCV. Endovascular thrombectomy for basilar artery occlusion: translating research findings into clinical practice. Lancet Neurol 2023;22:330-337.
crossref pmid
40. Lin CH, Liebeskind DS, Ovbiagele B, Lee M, Saver JL. Efficacy of endovascular therapy for basilar and vertebral artery occlusion: a systematic review and meta-analysis of randomized controlled trials. Eur J Intern Med 2023;110:22-28.
crossref pmid
41. Vergouwen MD, Algra A, Pfefferkorn T, Weimar C, Rueckert CM, Thijs V, et al. Time is brain(stem) in basilar artery occlusion. Stroke 2012;43:3003-3006.
crossref pmid
42. Alemseged F, Nguyen TN, Alverne FM, Liu X, Schonewille WJ, Nogueira RG. Endovascular therapy for basilar artery occlusion. Stroke 2023;54:1127-1137.
crossref pmid
43. Kawano H, Inatomi Y, Hirano T, Yonehara T. Vertebral artery stump syndrome in acute ischemic stroke. J Neurol Sci 2013;324:74-79.
crossref pmid
44. Johansson E, Cuadrado-Godia E, Hayden D, Bjellerup J, Ois A, Roquer J, et al. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: a pooled analysis. Neurology 2016;86:498-504.
crossref pmid
45. Jadhav AP, Zaidat OO, Liebeskind DS, Yavagal DR, Haussen DC, Hellinger FR Jr, et al. Emergent management of tandem lesions in acute ischemic stroke. Stroke 2019;50:428-433.
crossref pmid
46. Zhu F, Hossu G, Soudant M, Richard S, Achit H, Beguinet M, et al. Effect of emergent carotid stenting during endovascular therapy for acute anterior circulation stroke patients with tandem occlusion: a multicenter, randomized, clinical trial (TITAN) protocol. Int J Stroke 2021;16:342-348.
pmid


ABOUT JoS
AUTHOR INFORMATION
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
Editorial Office
Department of Neurology, Asan Medical Center,Ulsan University College of Medicine
88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Submission, status and progress, etc ⟫ E-mail: editor@j-stroke.org
Website and system ⟫ E-mail: journal@m2community.co.kr
Publishing company ⟫ E-mail: ka72sus@smileml.com
Developed in M2PI
Copyright © 2025 by Korean Stroke Society.
Close layer
prev next